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ABSTRACT
Acute kidney injury (AKI) is a major health threat worldwide. The literature on herbal intervention in AKI was searched from English and
Chinese databases and reports were critically analyzed in terms of preventing AKI, promoting repair and regeneration, enhancing extrarenal
clearance of uremic toxins, and preventing progression to chronic kidney disease (CKD). Altogether, 16 herbal formulae and a few extracts
derived from individual herbs were reported to prevent or mitigate AKI in animal models induced by renal ischemia/reperfusion, cisplastin,
gentamicin, glycerol, adenine, sepsis or physical exhaustion. Four formulae and six individual herbs were reported to accelerate recovery and/
or to prevent CKD in established AKI animal models. Intrarectal herbal medicines, with or without simultaneous oral administration, were
reported in six clinical trials and in an animal model to increase extrarenal clearance of uremic toxins. Additional 13 clinical trials reported
oral or intravenous herbal interventions in AKI of different etiologies. Despite recurring problems, notably poor compliance with good practice
guidelines for clinical trials and for authentication, naming and quality control of herbal materials, accumulating experimental data on the
preventive effects of herbal medicines in AKI look encouraging and urge for better, definitive trials to guide clinical practice. Herbal enemas
promoting extrarenal clearance of uremic toxins seem cost-effective, but better clinical evidence is certainly needed before any affirmative
recommendation be made for AKI patients without access to dialysis. New frontiers, however, lie in those herbal remedies that promote repair/
regeneration and prevent chronicity after AKI. Recent experimental data suggest that this may be possible.
Key words: Acute renal failure, renoprotective, traditional Chinese medicine, herbal medicinal products, traditional medicine
Abbreviations: AKI: acute kidney injury; AKIN: Acute Kidney Injury Network; αSMA: α smooth muscle actin; ARF: acute renal failure; ATN:
acute tubular necrosis; BUN: blood urea nitrogen; CAT: catalase; CKD: chronic kidney disease; CXCL12: chemokine C-X-C motif ligand 12;
CXCR4: chemokine C-X-C motif receptor 4; CLP: cecal ligation and puncture; Cu-Zn-SOD: copper-zinc superoxide dismutase; ECM:
extracellular matrix; eGFR: estimated glomerular filtration rate; EMT: epithelial-to-mesenchymal transition; ESWL: extracorporeal shock wave
lithotripsy; FSP: fibroblast-specific protein 1; GSH: glutathione; GSH-Px: glutathione peroxidase; HMP: herbal medicinal product; HO-1:
heme oxygenase 1; ICAM-1: intercellular adhesion molecule-1; ICU: intensive care unit; IFN-γ: interferon-γ; IL: interleukin; iNOS: inducible
nitric oxide synthase; i.p.: intraperitoneally or intraperitoneal; I/R: ischemia/reperfusion; i.v.: intravenous or intravenously; JNK: c-Jun N-
terminal kinase; KDIGO: Kidney Disease Improving Global Outcomes; KIM-1: kidney injury molecule 1; LPS: lipopolysaccharides; MCP-1:
monocyte chemotactic protein 1; MDA: malondialdehyde; MMP9: matrix metalloproteinase 9; Mn-SOD: manganese superoxide dismutase;
NF-κB: nuclear factor κB; NGAL: neutrophil gelatinase-associated lipocalin; NO: nitric oxide; PCI: percutaneous coronary intervention;
PCNA: proliferating cell nuclear antigen; p.o.: per os (oral administration); pRIFLE: modified RIFLE guideline for pediatric use; RCT:
randomized controlled clinical trial; ROS/RNS: reactive oxygen/nitrogen species; RIFLE: Risk, Injury, Failure, Loss, and End-stage renal
disease; RPTECs: renal proximal tubular epithelial cells; Scr: serum creatinine; TCM: traditional Chinese medicine; TGF-β: transforming
growth factor β; TIMP1: tissue inhibitor of metalloproteinase 1; TNF-α: tumor necrosis factor-α; UUO: unilateral ureteral obstruction.
INTRODUCTION
Acute kidney injury (AKI), an abrupt renal damage and sudden
decline of kidney functions, notably results in rapid increase in
serum creatinine (Scr), blood urea nitrogen (BUN) and dysre-
gulation of extracellular volume and electrolytes in a short term.
Although AKI is also known as “kidney attack”, an analogy to
heart attack that mainly results from coronary atherosclerotic
heart disease[1, 2], the causes of AKI are much more complex,
including renal ischemia reperfusion (I/R), nephrotoxicity,
infection, glomerular and interstitial nephritides, obstructive
nephropathy, to mention a few. AKI may manifest an entire
spectrum of severity, ranging from minor changes in urinary
enzymes and Scr to severe cases needing dialysis and other renal
replacement therapy. The latter severe scenario is also known as
acute renal failure (ARF)[3].
On 14th March 2013, the 8th World Kidney Day was
celebrated worldwide to alert the public of an increasing
prevalence of AKI. Recent hospital studies in the developed
world report AKI in 3.2–9.6% of admissions, with overall in-
hospital mortality around 20%, and up to 50% in intensive
care unit (ICU). ARF requiring dialysis treatment occurs in
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5–6% of ICU patients, with an extremely high in-hospital
mortality rate of 60%. The take-home message of the World
Kidney Day was that AKI is very common, extremely
harmful, and largely preventable[4].
In conventional medicine, however, strategies towards AKI
are essentially preventive and supportive — avoidance of
nephrotoxic agents is advised to patients, preconditioning is
considered before exposure to a known AKI inducer, and
dialysis is offered if indicated. Little evidence has so far
supported any drug that specifically attenuates AKI or expedites
recovery. If patients survive their illness and do not present
premorbid chronic kidney disease (CKD), they typically recover
to dialysis independence. However, evidence suggests that
patients who have suffered an AKI are at increased risk of
subsequent CKD[5]. Indeed, although AKI and CKD were once
believed to be distinct disease entities, they are now increasingly
regarded as closely interconnected syndromes, which are risk
factors to each other and are both risk factors for cardiovascular
disease and all-cause mortality[6].
For renal diseases, traditional medicines may have both
contraindications, yielding or reinforcing nephrotoxicity, and
indications, addressing medical needs unmet in AKI and
CKD prevention and treatment — just like the “double-
edged sword” effects of botanicals that we recently high-
lighted in the more general context of fibrotic diseases[7]. On
one hand, some botanicals used in traditional medicine or
ethnic cuisine are known to induce or exacerbate AKI, retard
AKI recovery and/or promote AKI progression to CKD.
These should be administered with caution, if at all, and
prohibited in AKI; such nephrotoxic botanicals have raised
major clinical concerns and their avoidance or controlled use
has already an acknowledged place in worldwide renopro-
tective strategies[8–16]. On the other hand, some herbal
medicines might have therapeutic values for the prevention
and treatment of AKI. For example, silymarin is a lipophilic
extract of the seeds of Silybum marianum (L.) Gaertn., the
whole plant of which is also used in traditional Chinese
medicine (TCM) as Shuĭ Fēi Jì (Herba Silybi). The herbal
extract comprises three isomers of flavonolignans (silybin,
silydianin and silychristin) and two flavonoids (taxifolin and
quercetin) and its potential renoprotective effects in AKI/
CKD were recently reviewed by Dashti-Khavidaki et al[17]. In
line with this timely review, the present paper aims to
critically examine the experimental and clinical evidence
suggesting potential therapeutic values for herbal medicines,
especially those used in TCM in the context of AKI.
TCM is a function-oriented, syndrome differentiation-
based medical system that emphasizes Yin-Yang balance and
interrelation between different organs. The concept of the
functional organ shèn largely covers the functions of the
kidney in modern medicine and AKI is often diagnosed as xū
láo (vacuity taxation, fatigue), shuĭ zhŏng (water swelling,
edema), lóng bì (dribbling urinary block, auria), yuē nì
(vomiting, nausea), gua ̄n gé (block and repulsion, auria/
vomiting), and/or niào dú (uremia)[18]. Thus, herbal remedies
aiming at tonifying shèn, protecting the kidney, and dealing
with imbalance and functional disorders are prescribed
according to TCM theory and/or experiences of TCM
practitioners.
In this review, we aim to enlist emerging evidence on
efficacy, effectiveness and mechanisms of action of herbal
medicines in the prevention and treatment of AKI, by
focusing on four potential aspects: (i) preventing or mitigat-
ing induction of AKI; (ii) promoting repair or regeneration;
(iii) promoting extrarenal clearance of uremic toxins; and (iv)
preventing AKI progression to CKD (Fig. 1).
METHODS
To review the in vitro, in vivo and clinical renoprotective
studies of botanicals possibly relevant to the prevention and
treatment of AKI, PubMed and Scopus databases were
screened by searching (“Acute Kidney Injury” [Mesh] or
Acute-kidney-failure or Acute-renal-failure or Acute-kidney-
insufficiency or Acute-renal-insufficiency) AND (“Drugs,
Chinese Herbal” [Mesh] OR “Herbal Medicine” [Mesh]). In
order to retrieve those randomized clinical studies and
experimental studies published in Chinese, especially those
on TCM, the China National Knowledge Infrastructure (www.
global.cnki.net) and the Wanfang Data (www.wanfangdata.
com) were accessed. The strategy used to search Chinese
databases was (急性肾功能不全 OR急性肾衰OR急性肾功
能衰竭 OR急性肾损伤OR急性肾损) AND (中药OR中医
OR中西医 OR汤 OR方 OR法 OR治则 OR草药 OR回药
OR蒙药 OR藏药 OR滇药) AND (治疗 OR预防 OR干预).
Three reviewers independently scrutinized the titles and
abstracts. Full manuscripts likely relevant to herbal medicines
for the prevention and treatment of AKI were obtained and
analyzed by at least two reviewers. Final decisions on addition
and inclusion were made on examination of the full manu-
scripts, including brief communications, based on the rele-
vance to the focus of this search. As we cannot exclude the
possibility that a paper poorly written may have important
contents of value to inspire future quality studies, we have not
excluded any paper on the grounds of poor quality; instead, we
introduce papers with higher quality with more details, while
only briefly mentioning those with poorer quality. Meanwhile,
we have pointed out common problems, as well as specific
Figure 1. Four possible therapeutic effects of herbal remedies in
prevention and treatment of AKI.
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weaknesses of each paper as far as we can in related texts and
tables. Nonetheless, interested readers are invited to read any
cited papers themselves to make their own judgements. To
facilitate access to Chinese literature not cited by Pubmed, we
have included correspondingWanfang Data web links to these
papers in the REFERENCES section.
Throughout this manuscript, scientific names and author-
ity names of medicinal plants will only be shown when
authentication of an herb was reported in the original
publication[19]. Wherever information on authentication is
unavailable, herbs used in TCM are referred to as accented
Chinese pinyin names followed by, in brackets, the English
pharmaceutical names retrieved from http://dict.paradigm-
pubs.com/test31.htm.
BOTANICALS FOR AKI: EXPERIMENTAL
STUDIES
1. Preventing and alleviating AKI
1.1 Ischemia/reperfusion (I/R) kidney injury
I/R is one of the most common causes of AKI and herbal
entities have been reported effective in preventing I/R-
induced AKI in animal models.
In TCM, two or more herbs are often used together as
herbal formulae. Those formulae reportedly preventing I/R-
induced AKI are shown in Table 1. We summarize reports on
the preventive effects of herbal formulae, individual herbs
and pure compounds of an herbal origin, as follows.
A preventive effect on I/R-induced AKI in rats has been
reported for the formula Dang Gui Bu Xue Tang (DGBXT),
comprising huáng qí (Astragali Radix) and da ̄ng guī (Angel-
icae Sinensis Radix). DGBXT (2 ml, by gavage, once daily)
administered for 3 days before clamping and then continued
for another 3 days significantly repressed the rise of Scr 24h
and 48h after reperfusion, as compared with the control group,
which were given distilled water instead of DGBXT. DGBXT
also significantly increased the percentage of tubular cells
expressing proliferating cell nuclear antigen (PCNA) and
increased renal c-Jun N-terminal kinase (JNK) activity[20].
Wen-Pi-Tang administered by gavage for 30 days was also
reported to prevent I/R-induced AKI in rats, preventing the rise
of Scr and BUN and reducing apoptosis in the kidney[21]. In a
renal tubular epithelial cell line, Wen-Pi-Tang, as well as three
of its ingredients, dà huáng (Rhei Radix et Rhizoma; Rheum
officinale Baillon), gān caŏ (Glycyrrhizae Radix; Glycyrrhiza
glabra Linn. var. glandulifera Regel et Herder) and rén shēn
(Ginseng Radix; Panax ginseng C.A. Meyer), but not the other
two ingredients, were shown to reduce cellular malondialdehyde
(MDA) contents and prevent cell death induced by hypoxia-
reoxygenation. Epicatechin 3-O-gallate and licochalcone A,
major polyphenols of dà huáng and gan̄ caŏ respectively, also
showed similar protective effects in this in vitro model[22].
In an I/R-induced AKI mouse model, Wen-Pi-Tang-Hab-
Wu-Ling-San, administered orally for 14 days prior to I/R
until the end of the study, prevented I/R-induced Scr rise and
renal tubular injury, while preserving the renal activities of
copper-zinc (Cu-Zn-SOD) and manganese superoxide
dismutases (Mn-SOD) and reducing lipid peroxidation and
hydrogen peroxide production[23].
Shenhua Tablet (also known as Fufang Shenhua Tablet or
Compound Shenhua Tablet), given to rats by gavage 7 days
prior to I/R intervention, reduced Scr, serum interleukin-8
(IL-8), serum interferon-γ (IFN-γ) and renal expression of
Toll-like receptor (TLR)-2 and -4[24]. The pretreatment
reduced Na+-K+-ATPase relocalization from the apical to
the basal membrane of tubular epithelial cells, suggesting
that it protected the renal tubules from I/R-induced
depolarity[32].
Cordyceps sinensis (Berk.) Sacc. is a fungus that parasites
caterpillars and its fruiting body is used in TCM as dōng chóng
xià căo (Cordyceps) for tonifying shèn, which may be positive
for AKI patients (as detailed later in Section 4). Modern
research validated a renoprotective activity mediated by
enhancement of antioxidative defenses[25]. In an I/R-induced
AKI model in rats, Shahed et al. reported that i.p. injection of a
Cordyceps sinensis extract 1 h before renal I/R procedure
significantly repressed Scr rise, suppressed the mRNA expres-
sion of monocyte chemotactic protein 1 (MCP-1), tumor
necrosis factor α (TNF-α), heme oxygenase 1 (HO-1),
inducible nitric oxide synthase (iNOS), Fas and Fas ligand, as
well as caspase 3 activity in the I/R kidney, indicating a likely
down-regulation of apoptotic and pro-inflammatory signal-
ling[26]. Renoprotective effects of Cordyceps sinensis were also
reported by Wang et al., who showed that Scr of rats orally
receiving a commercialized fermented Cordyceps sinensis
extract (Corbrin capsule, Bailing Jiaonang, Bailing capsule or
Bailing granule) for 2 days before I/R recovered faster. The
authors attributed this effect to an induction of chemokine C-
X-C motif ligand 12/chemokine C-X-C motif receptor 4
(CXCL12/CXCR4) signaling and alleviation of senescence[27].
Da ̄n shēn (Salviae Miltiorrhizae Radix; Salvia miltiorrhiza
Bunge (Labiatae)), an herb commonly used in TCM for its
acknowledged capacity of promoting blood circulation and
removing blood stasis, was also reported to have protective
effects in I/R-induced AKI. Rats orally administered an
ethanolic extract of the herb for 20 days had blunted rises
in Scr, BUN, circulating IL-6, IL-8, TNF-α and renal MDA,
and increased renal SOD, catalase (CAT), glutathione (GSH)
and glutathione peroxidase (GSH-Px)[28]. It was proposed
that the renoprotective effects of the herb was at least in part
attributable to its capacity to repress excessive nitric oxide
(NO) production and its subsequent transformation into the
pro-oxidant peroxynitrite (ONOO−); indeed S. miltiorrhiza
aqueous extract and isolated compounds (caffeic acid and its
oligomers, rosmarinic acid, lithospermic acid, lithospermic
acid B and magnesium lithospermate B) dose-dependently
reduced NO production from activated macrophages[29].
Picroliv, a mixture of iridoid glycosides extracted from Hú
húang lían (Picrorhizae Rhizoma; Picrorhiza kurrooa Royle
ex Benth-unresolved botanical name, consulted on 6th June
2015, www.theplantlist.org), was suggested of beneficial
effects in a rat model of I/R-induced AKI. Although renal
functional parameters (e.g. Scr and BUN) were not reported,
daily oral administration of picroliv for a week improved
www.wjtcm.org 49 July 2015 |Vol. 1 | Issue 3
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renal GSH, GSH-Px and SOD, and reduced renal MDA,
intercellular adhesion molecule-1 (ICAM-1) and apoptosis,
suggesting antioxidative, anti-inflammatory, and renoprotec-
tive potentials[30].
Ligustrazine, also known as tetramethylpyrazine, is a
compound purified from chua ̄n xiōng (Chuanxiong Rhi-
zoma; Ligusticum striatum DC.). In unilaterally nephrecto-
mised mice subjected to renal I/R, intraperitoneal (i.p.)
injection of ligustrazine 30 min before the I/R procedure
significantly blunted rises in Scr and BUN, while increasing
renal Bcl-2 and SOD, suppressing renal tubular necrosis and
apoptosis, and reducing renal MDA and ICAM-1[31].
Oral administration of astragaloside IV, a triterpenoid
glycoside isolated from Astragalus membranaceus (Fisch.)
Bunge, was also reported to prevent I/R-induced AKI in rats,
repressing BUN, Scr, serum IL-8 and IFN-γ, reducing renal
TLR-2 and TLR-4 and kidney injury molecule 1 (KIM-1)
expression, while preventing the loss of renal Na+-K+-
ATPase[32]. In another independent report of I/R-induced
AKI in rats, astragaloside IV pretreatment for a week reduced
BUN, Scr, serum cystatin C, neutrophil gelatinase-associated
lipocalin (NGAL) and urinary KIM-1, reduced oxidative
stress and tubular cell apoptosis, while increasing Bcl-2
expression, reducing p38 mitogen-activated protein kinase
phosphorylation, and Bax expression[33].
Notoginsenoside R1 is a triterpenoid saponin extracted
from sān qī (Notoginseng Radix; Panax notoginseng (Burkill)
F. H. Chen), an herb with a long history of traditional use for
the treatment of various cardiovascular diseases in China,
Korea, and Japan. The compound has antioxidant, anti-
inflammatory, anti-apoptotic and immune-stimulatory prop-
erties and was recently reported to accelerate structural and
functional recovery of I/R-injured kidneys in rats. I.p. injection
of the compound 1 h before I/R procedure did not affect the
peak of Scr rise 24h after I/R, but significantly reduced Scr at
72h after I/R. It notably promoted Bcl2 expression, suppressed
renal myeloperoxidase, TNF-α, p38 mitogen-activated protein
kinase and nuclear factor κ B (NF-κ B), and reduced tubular
apoptosis[34]
1.2 AKI induced by nephrotoxicants
Nephrotoxicants, notably some antibiotics, anti-cancer drugs
and contrast agents, are another major causes of AKI. Nine
herbal formulae (Table 2), a number of multi-component
herbal extracts and pure herbal compounds reportedly
prevented and/or mitigated experimental AKI induced by
different nephrotoxicants.
Cisplatin-induced AKI Cisplatin is an effective and com-
monly used chemotherapy drug against many cancers and its
nephrotoxicity is a major dose-limiting side effect. Gao et al.
reported that pretreatment for three days with a “Recipe for
nourishing kidney and activating blood” followed by three
more days of treatment after cisplatin injection in mice
significantly reduced cisplatin-induced rise of Scr and
ameliorated acute tubular necrosis (ATN)[35].
When orally administered in rats once daily for 23 days
before and 5 days after cisplatin injection, an aqueous extract
of hóng shēn (Ginseng Radix Rubra; steamed roots of Panax
ginseng C.A. Meyer) reduced cisplatin-induced renal expres-
sion of inflammatory cytokines and renal oxidative stress,
mitigated renal apoptosis and AKI renal pathology, and
attenuated Scr and BUN rises[36]. Furthermore, a Korean-
Chinese collaboration reported a new type of hóng shēn,
known as Sun Ginseng, which is processed at higher
temperature and pressure and contains much higher
Table 1. Formulae for preventing I/R-induced AKI.
Formula Ingredients References
Dang Gui Bu Xue Tang 2 herbs: huáng qí (Astragali Radix) and dāng guı¯ (Angelicae Sinensis Radix) [20]
Wen-Pi-Tang 5 authenticated herbs: dà huáng (Rhei Radix et Rhizoma; Rheum officinale
Baillon), rén shēn (Ginseng Radix; Panax ginseng C.A. Meyer), gān căo
(Glycyrrhizae Radix; Glycyrrhiza glabra Linn. var. glandulifera Regel et Herder),
gān jiāng (Zingiberis Rhizoma; Zingiber officinale Roscoe), and fù zı˘ (Aconiti
Radix Lateralis Praeparata; Aconitum japonicum Thunberg)
[21, 22]
Wen-Pi-Tang-Hab-Wu-Ling-San 14 authenticated herbs: dăng shēn (Codonopsis Radix; Codonopsis pilosula
(Fr.) Nannf), dān shēn (Salviae Miltiorrhizae Radix; Salvia miltiorrhiza Bunge),
bàn xià (Pinelliae Rhizoma; Pinellia ternata (Thunb.) Makino), huáng lián
(Coptidis Rhizoma; Coptis chinensis Franch.), yín yáng huò (Epimedii Herba;
Epimedium koreanum Nakai), dà huáng (Rhei Radix et Rhizoma; Rheum
palmatum L.), zı˘ su¯ yè (Perillae Folium; Perilla frutescens (L.) Britton), gān căo
(Glycyrrhizae Radix; Glycyrrhiza uralensis Fisch), yīn chén hāo (Artemisiae
Capillaris Herba; Artemisia capillaris Thunb.), zé xiè (Alismatis Rhizoma; Alisma
plantago-aquatica L.), fú líng (Poria; Wolfiporia cocos (Schw.) Ryv. & Gibn –
the authors used its old Latin name Poria cocos Schw.), bái zhú (Atractylodis
Macrocephalae Rhizoma; Atractylodes macrocephala Koidz.), zhū líng
(Polyporus; Polyporus umbellatus (Pers.) Fries), and guì zhī (Cinnamomi
Ramulus; Cinnamomum cassia (L.) J.Presl).
[23, 79]
Shenhua Tablet 7 herbs: Huáng qí (Astragali Radix), nü̆ zhe¯n zı˘ (Ligustri Lucidi Fructus), sān
léng (Sparganii Rhizoma), bái zhú (Atractylodis Macrocephalae Rhizoma), é
zhú (Curcumae Rhizoma), jı¯n yín huā (Lonicerae Flos), sháo yào (Paeoniae
Radix).
[24]
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Table 2. Formulae for preventing nephrotoxicant-induced AKI.
Formula Ingredients Types of AKI (Reference)
Recipe for nourishing kidney and
activating blood
12 ingredients: she¯ng huáng qí (Astragali Radix Cruda), wu˘
wèi zı˘ (Schisandrae Fructus), dān she¯n (Salviae Miltiorrhizae
Radix), chuān xio¯ng (Chuanxiong Rhizoma), dà huáng (Rhei
Radix et Rhizoma), dà huáng tàn (Rhei Radix et Rhizoma
Charred), bàn zhı¯ lián (Scutellariae Barbatae Herba), yı¯n chén
hāo (Artemisiae Scopariae Herba),qı¯ng hāo (Artemisiae Annuae
Herba), căo jué míng (Cassiae Semen), pú huáng tàn (Typhae
Pollen Carbonisatum), wu˘ líng zhı¯ (Trogopteri Faeces), etc.
Cisplatin-induced AKI [35]
Gujingdan 10 herbs: Huáng qí (Astragali Radix), yì zhì rén (Alpiniae
Oxyphyllae Fructus), shān yào (Dioscoreae Rhizoma), dān she¯n
(Salviae Miltiorrhizae Radix), yín yáng huò (Epimedii Herba), tài zı˘
she¯n (Pseudostellariae Radix), dù zhòng (Eucommiae Cortex),
qiàn shí (Euryales Semen), dāng guı¯ (Angelicae Sinensis Radix),
and jı¯ nèi jı¯n (Galli Gigeriae Endothelium Corneum).
Gentamicin-induced AKI [44].
Shenkangning 8 herbs: Huáng qí (Astragali Radix), dàn fù piàn (Aconiti Radix
Lateralis Insalsa), yì mu˘ căo (Leonuri Herba), suŏ yáng
(Cynomorii Herba), dān she¯n (Salviae Miltiorrhizae Radix), fú líng
(Poria), zé xiè (Alismatis Rhizoma), and shān yào (Dioscoreae
Rhizoma).
Gentamicin-induced AKI [44]
Zhibai Dihuang Wan 8 authenticated herbs: shān zhu¯ yú (Corni Fructus; Cornus
officinalis Siebold & Zucc), shú dì huáng (Rehmanniae Radix
Praeparata; Rehmannia glutinosa (Gaertn.) DC.), shān yào
(Dioscoreae Rhizoma; Dioscorea oppositifolia L.), guān huáng
băi (Phellodendri Cortex & Orientalis; Phellodendron amurense
Rupr.), zhı¯ mu˘ (Anemarrhenae Rhizoma; Anemarrhena
asphodeloides Bunge), mu˘ dān pí (Moutan Cortex; Paeonia
suffruticosa Andrews), zé xiè (Alismatis Rhizoma; Alisma
plantago-aquatica L.), and fú líng (Poria; Wolfiporia cocos
(Schw.) Ryv. & Gibn – the authors used one of its older Latin
names Poria cocos (Schw.) Wolf)
Gentamicin-induced AKI [45]
VI-28 8 herbs: rén she¯n (Ginseng Radix), lù róng (Cervi Cornu
Pantotrichum), do¯ng chóng xià căo (Cordyceps), dān she¯n
(Salviae Miltiorrhizae Radix), jiu˘ cài zı˘ (Allii Tuberosi Semen), shé
chuáng zı˘ (Cnidii Fructus), wú zhu¯ yú (Evodiae Fructus), and
shān nài (Kaempferiae Rhizoma)
Gentamicin-induced AKI [46]
WH30+ 7 ingredients: Dà huáng (Rhei Radix et Rhizoma), dān she¯n
(Salviae Miltiorrhizae Radix), do¯ng chóng xià căo (Cordyceps), yì
mu˘ căo (Leonuri Herba), yín yáng huò (Epimedii Herba), huáng
qí (Astragali Radix), and dăng she¯n (Codonopsis Radix).
Glycerol-induced AKI [52]
Shenshuai Mixture (aka Shenshuai
Compound Medicine)
10 ingredients (only seven disclosed): She¯ng dì (Rehmanniae
Radix (Exsiccata seu Recens)), dà huáng (Rhei Radix et Rhizoma),
chì sháo (Paeoniae Radix Rubra), huáng lián (Coptidis Rhizoma),
dān pí (Moutan Cortex), zé xiè (Alismatis Rhizoma), and huá shí
(Talcum).
Glycerol-induced AKI. [53].[54]
Shensheng fang 4 ingredients: Huáng qí (Astragali Radix), yín yáng huò
(Epimedii Herba), shuı˘ zhì (Hirudo), shān zhā (Crataegi
Fructus), etc.
Glycerol-induced AKI [55]
Ermiao San 9 constituents: Cāng zhú (Atractylodis Rhizoma), huáng băi
(Phellodendri Cortex), dà huáng (Rhei Radix et Rhizoma), yì mu˘
căo (Leonuri Herba), bái huā shé shé căo (Oldenlandiae Herba),
zhu¯ líng (Polyporus), Huáng qí (Astragali Radix), niú xı¯
(Achyranthis Bidentatae Radix), guāng cí gu¯ (Tulipae Edulis
Tuber), etc.
Adenine and ethambutol
hydrochloride-induced AKI [56]
Fufang Xi Xian Cao Capsule 8 ingredients: Xı¯ xiān căo (Siegesbeckiae Herba), jı¯n qián căo
(Lysimachiae Herba), qín jiāo (Gentianae Macrophyllae Radix),
fáng jı˘ (Stephaniae Tetrandrae Radix), zhu¯ líng (Polyporus), zé xiè
(Alismatis Rhizoma), che¯ qián căo (Plantaginis Herba), niú xı¯
(Achyranthis Bidentatae Radix), etc.
Adenine and oteracil
potassium-induced AKI [57]
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concentrations of the ginsenosides unique to hóng shēn.
They found that a Sun Ginseng extract reduced cisplatin-
induced LLC-PK1 cell death more effectively than non-
processed ginseng. An activity-guided fractionation and
isolation identified ginsenosides Rh4 and Rk3 as the com-
pounds responsible for this cytoprotective activity[37].
Emodin, a naturally occurring anthraquinone derivative
isolated from dà huáng (Rhei Radix et Rhizoma; Rheum
officinale Baillon), has been reported to alleviate cisplatin-
induced nephrotoxicity in rats. Emodin treatment for 4 days
prior to and 5 days after cisplatin administration increased
renal GSH content, reduced oxidative stress and mitigated
cisplatin-induced tubular necrosis and rises of Scr and
BUN[38].
Líng Zhī, the fruiting body of the fungusGanoderma lucidum
(Curtis ex Fr.) P. Karst., has been used traditionally for
extending patient’s life span and promoting good health[39].
The major bioactive constituents of Ganoderma are polysac-
charides and triterpenes: more than 140 triterpenoids have been
reported, of which 50 are unique to G. lucidum[39]. These
triterpenoids have demonstrated a beneficial activity towards
cisplatin-induced oxidative stress in mice: a triterpene extract
(100 mg/kg body weight) prevented the renal failure in
preserving antioxidant enzymes (SOD, CAT and GSH-Px)
and restoring GSH concentrations[40].
Gān ca ̆o (Glycyrrhizae Radix; Glycyrrhiza glabra Linn. var.
glandulifera Regel et Herder) is well known for its detoxicat-
ing effects in TCM and is often used in herbal formulae for
the prevention of AKI. In a mouse model of cisplatin-
induced AKI, the protective effects of a ga ̄n căo-derived
compound, glycyrrhizic acid, and its metabolite 18β-glycyr-
rhetinic acid, were investigated. Oral administration of either
compound six days before and two days after cisplatin
treatment significantly reduced cisplatin-induced increases
of BUN, Scr, and serum lactate dehydrogenase three days
after cisplatin treament. Renal histopathological studies
indicated that either compound delayed the progression of
renal injury, including tubular necrosis, hyaline casts, and
tubular degeneration in response to cisplatin exposure. The
compounds reduced renal MDA, increased renal SOD, CAT,
GSH, GSH-Px, and HO-1 levels, and restored redox status
and inflammatory responses in cisplatin-treated mice to
almost normal levels. These protective effects are associated
with upregulation of nuclear factor E2-related protein and
downregulation of NF-κB in the kidney. The two compounds
also rendered renal tissue resistant to cisplatin-induced
cytoplasmic translocation of high mobility group box 1[41].
Da ̄ng guī (Angelicae Sinensis Radix; Angelica sinensis
(Oliv.) Diels (Apiaceae)) is often used in herbal formulae
for AKI. A methanolic extract of the herb was reported to
reduce apoptosis, increase survival and enhance proliferation
and migration of HK-2 human kidney proximal tubular cells
exposed to cisplatin[42].
Wŭ wèi zĭ (Schisandrae Fructus; Schisandra chinensis
(Turcz.) Baill.) is also used in some herbal formulae for the
prevention of AKI. Schizandrin and schizandrin B, com-
pounds isolated from wŭ wèi zĭ, have been reported to
alleviate apoptosis, reduce collagen accumulation and
enhance regeneration capacities in HK-2 human proximal
tubular cells exposed to cisplatin[43].
Gentamicin-induced AKI Gentamicin is a potent antibiotic
but its nephrotoxicity remains a major clinical concern.
Daily gavage of Gujingdan or Shenkangning, either start-
ing from one week before the first gentamicin injection or
after each gentamicin treatment, has been reported to prevent
gentamicin-induced AKI in rats. Both herbal remedies
reduced Scr, BUN, urinary N-acetyl-beta-D-glucosaminidase
(NAG), renal cortical MDA, and increased renal cortical
SOD, Na+-K+-ATPase, Ca2+-ATPase and Mg2+-ATPase[44].
Oral administration of an extract of the classic Shèn-tonic
formula Zhibai Dihuang Wan before each gentamicin injec-
tion for 10 days was also reported to significantly attenuate
gentamicin-induced apoptosis of renal tubular cells and
prevented rises of BUN and Scr in mice[45]. This renopro-
tective effect was supported by in vitro data that the Zhibai
Dihuang Wan extract and two constituent herbs of the
formula, gua ̄n huáng băi (Phellodendri Cortex & Orientalis;
Phellodendron amurense Rupr.) and zhī mŭ (Anemarrhenae
Rhizoma; Anemarrhena asphodeloides Bunge), attenuated
gentamicin-induced Bcl2 repression, caspase-3 activation
and apoptosis in NRK-52E rat kidney epithelial cells[45].
Pretreatment for two days, followed by 10 days of co-
treatment with VI-28 (by gavage), has been reported to
prevent gentamicin-induced rises in Scr and BUN, and to
enhance the renal mitochondrial antioxidant system in rats,
as indicated by dose-dependent increases in the level/
activities of reduced GSH, Mn-SOD, Se-GSH-px GSH
reductase and GSH-S-transferases[46].
Dōng chóng xià ca ̆o (Cordyceps; Cordyceps sinensis (Berk.)
Sacc.) was reported to ameliorate gentamicin-induced
nephrotoxicity in rats, as evident from the less prominent
increment of BUN, Scr, sodium excretion, urinary NAG and
less severe histopathological changes in the Cordyceps
treatment group[47].
An aqueous extract of hóng shēn (Ginseng Radix Rubra;
steamed roots of Panax ginseng C.A. Meyer), was reported to
significantly reduce gentamicin-induced rises in Scr, BUN,
proteinuria, urinary excretion of 8-hydroxy-2’-deoxyguano-
sine, renal Bax and cytochrome-c, renal caspase-9 and
caspase-3 activation, and renal tubular cell apoptosis, while
restoring Bcl-2 expression and increasing GSH in renal
cortex in a mouse model of gentamicin-induced AKI; it also
prevented gentamicin-induced apoptosis and oxidative stress
in NRK-52E rat renal tubular cells[48].
Ligustrazine, which was reported effective in preventing I/
R-induced AKI in mice[31], was also reported to abrogate
gentamicin-induced apoptosis of renal tubular cells in
rats[49]. In cultured NRK-52E rat kidney tubular cells,
ligustrazine pretreatment protected against gentamicin-
induced apoptosis and, dose-dependently, repressed genta-
micin-induced generation of reactive oxygen species, reduced
caspase-3, caspase-8 and caspase-9 activities, prevented
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cytochrome c release, TNF-α excretion and NF-κB activity,
increased Bcl-xL expression[50].
Schizandrin B, a derivative from wŭ wèi zĭ discussed
previously for its protection of HK-2 human proximal
tubular cells exposed to cisplatin, also ameliorated the
oxidative stress in renal mitochondria of rats exposed to
gentamicin. The protection was attributed to an enhanced
antioxidant status (as observed via GSH and α-tocopherol
levels and Mn-SOD activity), leading to an improvement in
mitochondrial structure and function (highlighted by ATP,
MDA levels, Ca2+ loading and cytochrome c release). As a
result, the kidney structure and function were preserved and
normal Scr and BUN levels were restored[51].
Glycerol-induced AKI Pretreatment with WH30+, a 7-herb
TCM formula, for 10 days has been reported to attentuate
glycerol-induced AKI in rats, preventing rises of Scr and
BUN[52]. Treatment with Shenshuai Mixture (“Shenshuai
Compound Medicine”), a 10-herb TCM formula (by gavage,
twice daily for 5 days), immediately after intramuscular
injection of glycerol in rats was also reported to significantly
reduce plasma endothelin-1 and serum TNF-α, increase
serum NO, enhance PCNA expression in renal tubular cells,
and significantly attentuate rises of Scr and BUN[53, 54]. In
another report, six days of Shenshengfang pretreatment
attenuated a similar AKI model, increasing the urinary
output and reducing serum potassium 24 h after glycerol
injection, and reducing Scr and BUN at 24 h and 72 h[55].
Adenine-induced AKI AKI and/or CKD can be induced by
adenine due to hyperuricemia, tubular obstruction and tubu-
lointerstial nephritis. Ermiao San was reported to prevent AKI
induced by adenine and ethambutol hydrochloride in rats when
administered by daily gavage from day 1 of the nephrotoxic
treatment. The herbal extract significantly suppressed the rises
of BUN and Scr on days 7, 14 and 21, and significantly reduced
serum uric acid on days 14 and 21[56].
When administered daily along with adenine and oteracil
potassium in rats, Fufang Xi Xian Cao Capsules were
reported to alleviate AKI induced by adenine and oteracil
potassium, preventing rises of serum uric acid, BUN and Scr
on days 7, 14 and 21[57].
A decoction of dì yú (Sanguisorbae Radix; Sanguisorba
officinalis L.) was reported to alleviate AKI induced by adenine
and yeast extract in rats. Administered daily by gavage along
with the nephrotoxic treatment for 6 weeks, the decoction dose-
dependently increased urinary excretion and reduced serum
concentration of uric acid without affecting serum xanthine
oxidase activity; the herbal decoction dose-dependently reduced
BUN and Scr, reduced tubular dilation, cast formation, ATN,
dilation of the Bowman’s capsule and reducedmortality (6.25%,
18.75% in high- and low-dose decoction treatment groups vs
37.50% in non-treated group)[58].
AKI induced by contrast agents Breviscapine, an extract
from dēng zhăn xì xīn (Erigerontis Herba; Erigeron brevisca-
pus (Vaniot) Hand.-Mazz.) principally enriched in the glyco-
flavone scutellarin, was found effective to prevent AKI
induced by a single intravenous injection of iopromide
(Ultravist 370). Daily peritoneal injections for three days,
starting from the day of intravenous injection of the contrast
medium, significantly reduced Scr and serum cystatin C, and
prevented the reduction of renal Na+/K+-ATPase activity 3
days after injection of the contrast medium[59].
Oral administration of astragaloside IV for a week prior to
injection of iopamidol was reported to alleviate the contrast
agent-induced AKI and preserved renal function; histological
examinations revealed reduced ATN, which was correlated
with reductions of BUN, Scr, serum cystatin C and NGAL, as
well as urinary KIM-1. In the astragaloside IV treatment
group, the renal oxidative stress was reduced, with notably
decreased MDA and increased CAT and SOD activities;
decreased Bax and increased Bcl2 renal expression, reduced
caspase-3 activation and apoptosis were also observed[33].
AKI induced by chromium, mercury, iron or lead. Chro-
mium intoxication can induce both AKI and CKD. An
extract of total tannins, but not anthraquinones, of dà huáng
(Rhei Radix et Rhizoma; Rheum officinale Baill.) was reported
to prevent chromium-induced AKI in rats[60].
Mercuric chloride causes oxidant AKI that affects mainly
proximal tubules. In rats, schizandrin B pretreatment (oral
administration for 9 days) ameliorated i.p. mercury-induced
tubular and mitochondrial damage, reduced heat shock
proteins in the renal cortex, increased cytochrome c oxidase
and restored eNOS and nNOS in glomeruli[61].
I.p. injection of nephrotoxic doses of iron dextran for 2
weeks or lead for 10 days induces AKI in mice. I.p.
administration of Danshen injection (an aqueous extract of
dān shēn (Salviae Miltiorrhizae Radix), 4 hours before each
nephrotoxic injection led to significant improvements of body
weight and decreased iron or lead levels in the kidney. In both
AKI models, Danshen injection reduced BUN, Scr and renal
MDA, and enhanced renal SOD and GSH-Px activities[62, 63]
AKI/CKD induced by organic xenobiotics A single adminis-
tration of a nephrotoxic dose of absolute ethanol to fasted
mice produces extensive AKI. A líng zhī (Ganoderma;
Ganoderma lucidum (Curtis ex Fr.) P. Karst.) aqueous
decoction was reported to dose-dependently exert antioxida-
tive effect on kidney lipid peroxidation and alleviate ethanol-
induced nephrotoxicity in a mouse model[64]. Oral pretreat-
ment with ligustrazine, at least in part, prevented ethanol-
induced AKI due to its superoxide scavenging effect[65].
Schizandrin B was reported to ameliorate cyclosporine A-
induced AKI in mice, attenuating histopathological changes
and alleviating the rises in BUN and Scr. Schizandrin B also
decreased renal MDA and increased GSH levels in cyclos-
porine A-treated mice. Furthermore, in cyclosporine A-
treated HK-2 cells, schizandrin B reduced apoptosis,
increased intracellular GSH and ATP levels and attenuated
the generation of reactive oxygen species[66].
An aqueous extract of máo shŭ (Dioscoreae Alatae Tuber;
Dioscorea alata L.) was reported to alleviate AKI induced by
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acetaminophen in rats, partially preventing rises in Scr, BUN
and serum uric acid[67].
Aflatoxin B1 is a potent hepatotoxic and hepatocarcino-
genic mycotoxin that can also induce AKI. Marked increases
in lipid peroxide levels in kidneys and liver and a con-
comitant decrease in antioxidant enzymes levels (SOD,
catalase, GSH transferase, etc) were observed in aflatoxin
B1-intoxicated rats, while picroliv and silymarin treatments
both reversed the conditions to almost normal level[68].
1.3 AKI induced by sepsis, endotoxin or over-exercise
Sepsis, infection and harsh exercise (such as extreme physical
exercise) are also important causes of AKI. Table 3 sum-
marizes the various herbal formulae and remedies reported to
prevent AKI induced by these causes.
In rats, an i.p. injection of Xuebijing, a proprietary extract
mainly containing five herbs, significantly reduced the rises
of Scr, BUN, serum β2-microglobulin and renal IL-6
observed after sepsis induction by cecal ligation and puncture
(CLP)[69]. A post-CLP intravenous injection of an extract of
huáng qí (Astragali Radix) significantly reduced serum
cystatin C and suppressed renal IL-1β and TNF-α expression
and decreased renal NFκB activity 8 and 24 hours after
CLP[70]. In rats, upon CLP, an i.p. injection of an extract of
kŭ ma ̆i cài (Ixeris Denticulatae Herba; Ixeris sonchifolia
(Bunge) Hance) significantly prevented rises of Scr and renal
MDA and increased renal SOD after 3, 6 and 24 hours[71].
Lipopolysaccharides (LPS) can also induce AKI in mice. 1
h before i.p. injection of LPS, an i.p. injection of ginseng
panaxadiol saponins extracted from rén shēn (Ginseng
Radix; Panax ginseng C. A. Meyer) reduced Scr, renal
iNOS, NO and MDS, increased renal SOD and reduced
apoptosis in the kidney[72].
Exhaustingly exercised rats developed AKI within 8 weeks,
which is more pronounced under conditions of high
temperature, high humidity and bearing weight, etc. Yishen
Huanji Decoction treatment prevented rises in Scr, BUN,
urinary albumin and NAG excretion, and preserved renal
Na+-K+-ATPase activity in these models[73,74].
2. Promoting repair and regeneration, increasing
extrarenal uremic toxin removal and preventing
chronic lesions after AKI
Most published experimental investigations focused on pre-
vention and mitigation of AKI through herbal pretreatment or
simultaneous use of herbal medicines with inducers of AKI.
Nevertheless, some emerging evidence supports a potential for
herbal formulae (Table 4), extracts of individual herbs and
pure herbal compounds in promoting repair and regeneration,
increasing extrarenal uremic toxin removal and preventing
chronic lesions in AKI, either by starting treatment in the early
stages of AKI or when AKI is already established.
Promoting repair and regeneration after AKI As recently
reviewed by Wang et al[75], a possibility exists that herbal
medicines exert actions through prohealing progenitor cells.
Direct evidence for botanicals having therapeutic effects on
AKI through such cells is however scarce. Interestingly, it was
recently reported that exposure of human adipose-derived
mesenchymal stem cells to astragaloside IV increased stem
cell migration to cisplatin-damaged renal tubular epithelial
cells, suppressed proinflammatory cytokine and chemokine
expression and increased erythropoietin and insulin-like
growth factor 1 expression[76]. In addition, in in vitro and
in vivo AKI models, herbal remedies have been reported to
promote proliferation of tubular epithelial cells[27,53,77,78].
Increasing extrarenal removal of uremic toxins after AKI In
a rat model with established gentamicin-induced AKI, both a
decoction of Huanghuai Wendan Recipe, administered by
gavage, and the Shenshuaikang enema, administered intrar-
ectally, significantly reduced Scr and BUN and reduced the
histology of tubular injury[18].
Preventing chronic lesions Effects of herbal medicines on
long-term outcomes in AKI have been rarely studied. None-
theless, some emerging evidence suggests that herbal medi-
cines could repress chronic renal lesions in AKI induced by
I/R, aristolochic acid-containing herb or cisplatin.
Wen-Pi-Tang-Hab-Wu-Ling-San, when administered to
mice for 12 days starting from 2 days after renal I/R, was
reported to prevent I/R-induced decrease of renal SOD
activities, reduce lipid peroxidation and hydrogen peroxide
production, attenuate renal phosphorylation of mitogen-
activated protein kinases and activation of NF-κB and,
importantly, prevented renal fibrosis[79].
Aristolochic acid-containing herbs are known to induce both
AKI and CKD. Rats fed simultaneously with Wen Yang Huo
Xue Fang and guan̄ mù tōng (Aristolochiae Manshurensis
Caulis; Aristolochia manshuriensis Kom.) decoctions for 20
Table 3. Formulae for preventing AKI induced by sepsis or over-exercise.
Formula Ingredients
Type of AKI
(Reference)
Xuebijing 5 herbs: Hóng huā (Carthami Flos), chì sháo (Paeoniae Radix Rubra), chuān
xio¯ng (Chuanxiong Rhizoma), dān she¯n (Salviae Miltiorrhizae Radix), dāng guı¯
(Angelicae Sinensis Radix).
Sepsis-induced AKI [69]
Yishen Huanji Decoction 10 herbs: dăng she¯n (Codonopsis Radix), zhì huáng qí (Astragali Radix cum
Liquido Fricta), hóng jı˘ng tiān (Rhodiolae Herba), yín yáng huò (Epimedii
Herba), xiān hè căo (Agrimoniae Herba), go¯ng láo yè (Mahoniae Folium), qiān
nián jiàn (Homalomenae Rhizoma), wu˘ jiā pí (Acanthopanacis Cortex), xià ku¯
căo (Prunellae Spica), zhı¯ zı˘ (Gardeniae Fructus).
Over-exercise induced
AKI [73, 74]
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weeks presented significantly reduced Scr, BUN and urinary
excretion of proteins, β2-microglobulin and NAG as well as
improved anemia. Thus, when administered early, this decoc-
tion attenuated the long-term chronic damage of the disease
model[80].
In HK-2 human kidney proximal tubular cells, a methanolic
extract of dāng guī (Angelicae Sinensis Radix; Angelica
sinensis) did not alleviate oxidative stress but reduced collagen
production upon cisplatin exposure. This coincided with
reduced activation of the β-catenin pathway, which is involved
in epithelial-to-mensenchymal transition (EMT) and fibrosis.
Deeper investigation on major bioactive compounds of the
herb (ferulic acid, Z-ligustilide and E-ligustilide) identified
ferulic acid as the most potent protectant; in a cisplatin-
mediated toxicity model using HK-2 cells, it not only reduced
apoptosis, but also reduced collagen accumulation and pre-
vented activation of the β-catenin pathway[42,78]. Thus,
whether such favorable effects can be translated into in vivo,
and whether Angelica sinensis compounds reduce long-term
chronic lesions in AKI deserve further studies. Similarly, some
herbal medicines, such as dān shēn (Salviae Miltiorrhizae
Radix; Salvia miltiorrhiza Bunge (Labiatae), huáng qí (Astra-
gali Radix; Astragalus membranaceus (Fisch.) Bunge), dōng
chóng xià cAo (Cordyceps; Cordyceps sinensis (Berk.) Sacc.),
and líng zhī (Ganoderma; Ganoderma lucidum (Curtis ex Fr.)
P. Karst.), have demonstrated favorable effects in preventing
and mitigating AKI, and also have promising anti-fibrotic
effects[7, 81, 82]. Thus, it awaits further investigations to find out
whether use of these herbs affects long-term outcomes in AKI
patients.
BOTANICALS FOR AKI: CLINICAL STUDIES
Clinical diagnosis of AKI has long been mainly based on
acute changes of Scr and urinary volume, but the detailed
criteria, dominated by expert opinions, differed internation-
ally. This started to change in the new millennium. Using
both evidence and consensus, international collaborations
have gained pace in standardizing the clinical definition of
the different stages of AKI, leading to publications of the
Risk, Injury, Failure, Loss, and End-stage renal disease
(RIFLE) guideline, the modified RIFLE guideline for pediatric
use (pRIFLE), and the AKI Network (AKIN) guidelines in
2004 and 2007. The RIFLE and AKIN guidelines were then
merged in 2012 to form the Kidney Disease Improving
Global Outcomes (KDIGO) guideline[83]. It was recom-
mended by a group of experts commissioned by the UK
National Institute of Health and Care Excellence that KDIGO
and pRIFLE guidelines be used for diagnosing adult and
pediatric AKI patients, respectively[83]. In view of the above
evolving clinical definition of AKI, it is not surprising that
published clinical studies have used a variety of criteria for
AKI diagnosis, as summarized in Tables 5 and 6.
There were altogether 19 randomized clinical trials on
herbal prevention and treatment of AKI: common weak-
nesses of these trials included lack of reporting authentication
and quality control of the herbal products (a problem shared
Table 4. Formulae for treatment of established AKI.
Formula Ingredients Type of AKI (Reference)
Huanghuai Wendan Recipe 10 herbs: Bàn xià (Pinelliae Rhizoma), chén pí (Citri Reticulatae
Pericarpium), fú ling (Poria), zhú rú (Bumbusae Caulis in Taenia), zhì
dà huáng (Rhei Radix et Rhizoma Preparata), she¯ng huái huā
(Sophorae Flos Crudus), bái huā shé shé căo (Oldenlandiae Herba),
gān căo (Glycyrrhizae Radix), she¯ng jiāng (Zingiberis Rhizoma
Recens), dà zăo (Jujubae Fructus).
Gentamicin-induced AKI [18]
Shenshuaikang enema 4 herbs: Tài zı˘ she¯n (Pseudostellariae Radix), dà huáng (Rhei Radix
et Rhizoma), hóng huā (Carthami Flos), gān căo (Glycyrrhizae
Radix).
Gentamicin-induced AKI [18]
Wen-Pi-Tang-Hab-Wu-Ling-San 14 herbs (Same as Table 1) : dăng she¯n (Codonopsis Radix;
Codonopsis pilosula (Fr.) Nannf), dān she¯n (Salviae Miltiorrhizae
Radix; Salvia miltiorrhiza Bunge), bàn xià (Pinelliae Rhizoma; Pinellia
ternata (Thunb.) Makino), huáng lián (Coptidis Rhizoma; Coptis
chinensis Franch.), yín yáng huò (Epimedii Herba; Epimedium
koreanum Nakai), dà huáng (Rhei Radix et Rhizoma; Rheum
palmatum L.), zı˘ su¯ yè (Perillae Folium; Perilla frutescens (L.) Britton),
gān căo (Glycyrrhizae Radix; Glycyrrhiza uralensis Fisch), yı¯n chén
hāo (Artemisiae Capillaris Herba; Artemisia capillaris Thunb.), zé xiè
(Alismatis Rhizoma; Alisma plantago-aquatica L.), fú líng (Poria;
Wolfiporia cocos (Schw.) Ryv. & Gibn – the authors used its old
Latin name Poria cocos Schw.), bái zhú (Atractylodis Macrocephalae
Rhizoma; Atractylodes macrocephala Koidz.), zhu¯ líng (Polyporus;
Polyporus umbellatus (Pers.) Fries), and guì zhı¯ (Cinnamomi
Ramulus; Cinnamomum cassia (L.) J.Presl).
I/R-induced AKI [79]
Wen Yang Huo Xue Fang 5 herbs: Táo rén (Persicae Semen), hóng huā (Carthami Flos), ròu
co¯ng róng (Cistanches Herba), xiān líng pí (Epimedii Herba) and dān
pí (Moutan Cortex).
Aristolochic acid-induced
AKI/CKD[80]
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by in vitro and in vivo studies, as reported in the preceding
section), small trial sizes, blank controls, and non-blinded
designs. Five randomized controlled trials (two published in
English and three in Chinese) were retrieved from the
Pubmed database — they were otherwise compliant with
the CONSORT guidelines (http://www.consort-statement.
org/), except for the aforementioned weaknesses (Table 5).
The remaining 14 were not indexed in Pubmed and were
retrieved from Chinese databases. They were all published in
Chinese (only five have titles and abstracts in English) by
authors from hospitals in counties (2/14) or small-to-
medium-sized cities (11/14), where medical resources and
resources for clinical trial training are generally limited; their
quality, as judged by the CONSORT guidelines, is thus
unsurprisingly poor (Table 6). These abstracts or brief
reports (0.5–2.5 pages) share weaknesses with those cited in
the Pubmed database. In addition, these papers hardly report
methodology of randomization, ethical approval and consent,
and rarely provide details of the baseline comparison between
treated and control groups. We describe Pubmed-cited
reports and also cover the reports cited only in Chinese
database (except one which is too confused for analysis), not
as conclusive evidence, but rather as possible sources of
experience, knowledge or information, which we hope will
promote future high-quality developments.
1. Pubmed-cited reports (Table 5)
Fermented dōng chóng xià căo (Cordyceps) for prevention of
contrast medium-induced AKI The preventive effects of
Corbrin Capsules, a commercially available fermented Cor-
dyceps powder, on contrast medium-induced AKI were
studied in patients with stable angina pectoris. 103 inpatients
were randomly divided into two groups: blank control
treatment (n=51) and Cordyceps treatment (n=52). Corbrin
Capsules (3 g, p.o., thrice daily), were given to the Cordyceps
group 3 days before angioplasty using low-osmolarity non-
ionic contrast media (iopamidol, i.v.) and 3 days after
angioplasty. Scr was assessed at the time of hospital admis-
sion and 1, 2, and 3 days after angioplasty. Urinary KIM-1,
NGAL and IL-18 were examined before angioplasty and 1
day after angioplasty. The prevalence of contrast medium-
induced nephropathy was 5.77% in the Cordyceps group and
11.76% in the blank control group (the difference was not
statistically significant). The post-procedure mean peak of
Scr, post-procedure increase in Scr levels from baseline, and
urinary KIM-1, NGAL and IL-18 after the procedure in the
Cordyceps group were significantly lower than those in the
control group[84].
Danhong Injection for prevention of contrast medium-induced
AKI The preventive effects of Danhong Injection, a com-
mercial product comprising extracts of da ̄n shēn (Salviae
Miltiorrhizae Radix) and hóng huā (Carthami Flos), were
studied on contrast medium-induced renal impairment after
percutaneous coronary intervention (PCI) using the contrast
medium ioperamide. Eighty patients were randomly assigned
to a blank control group and the Danhong treatment group,
n = 40/group. All patients received routine medicines such
as enteric-coated aspirin and metoprolol, as well as routine
rehydration therapy. For patients in the treatment group,
20 ml Danhong Injection was intravenously dripped by
adding in 250 ml normal saline from 2-3 days before PCI to
3 days afterwards, once daily. Scr, serum cystatin C, urinary
albumin, and β2-microglobulin were measured before and
24, 48, 72 h after PCI. 5 (12.5%) patients in the control
group and 2 (5.0%) in the treatment group had contrast
medium-induced nephropathy (the difference was not
statistically significant). However, the treatment group
had significantly lower Scr, serum cystatin C and urinary
β2-microglobulin 24h after PCI, had significantly lower
serum cystatin C, urinary β2-microglobulin and albumin
48h after PCI and had significantly lower urinary albumin
72h after PCI[85].
Qishen Huoxue Granule as an auxiliary treatment of AKI in
an intensive care unit The effects of Qishen Huoxue
Granule, a commercial product comprising extracts of 6
herbs, on AKI in ICU patients were studied in 52 AKI
patients randomly assigned to two groups: a blank control
group (n = 27) treated only by hemofiltration therapy and
the treatment group (n = 25) treated with Qishen Huoxue
Granule (10 g, by gavage, thrice daily) for 2 weeks in addition
to hemofiltration therapy. Mechanical ventilation and
vasoactive drugs were administered when necessary. It took
8.00 ± 1.02 days for urinary output to recover (>0.5 ml/kg/h)
in the treatment group, a significantly shorter time compared
to the blank control group (13.00 ± 0.95 days). Supporting
accelerated recovery of renal function, serum cystatin C was
lower in the treatment group at days 10 and 14. The needs
for mechanical ventilation and vasoactive drugs were sig-
nificantly lower in the treatment group, which tended to have
lower 28-day mortality (12% vs 29.6%) and fewer days of
ICU stay (19.25 ± 2.15 vs 21.00 ± 2.57), but the differences
were not statistically significant[86].
An 11-herb decoction for AKI induced by extracorporeal shock
wave lithotripsy (ESWL) 60 patients with renal calculus to
be treated by ESWL were randomly assigned to treatment
and blank control groups. Post-ESWL plasma NO, endothe-
lin-1 (ET-1), MDA and serum TNF-α significantly increased
in the control group, but not in the treatment group. The
difference between the groups was statistically significant. 72
h after ESWL, the levels of plasma SOD decreased in the
control but not in the treatment group; the plasma NO and
urinary β2-microglobulin were significantly lower in the
treatment group[87].
Chongcao Shenkang Capsules for preventing and treating AKI
due to epidemic hemorrhagic fever 150 AKI patients with
epidemic hemorrhagic fever were randomly assigned to the
treatment group (n = 76) and the blank control group (n =
74). All patients were given ribavirin and supporting
treatment to maintain electrolyte and water homeostasis
and the treatment group received Chongcao Shenkang
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Table 5. Herbal medicine prevention and treatment of AKI: Analysis of the five randomized controlled trials indexed in Pubmed.
Authors
Total
subject No.
(control,
treatment)
Randomization
methodology Herbal medicines Route Control
Blind design
and
concealment
of allocation
Consent
and
ethical
approval
Baseline
compar-
ability
AKI diagnosis
criteria
Zhao et al [84]. 103 (51, 52) Random number
table
Corbrin Capsules, a fermented do¯ng
chóng xià căo (Cordyceps) power.
p.o. Blank
control
None Yes Yes Contrast medium-induced
nephropathy was defined as Scr rise
≥0.5 mg/dl or ≥25% of basal level
within 3 days after exposure to
contrast medium, excluding other
etiology
Wang et al [85] 80 (40, 40) Random number
table
Danhong Injection, a commercial
product comprising extracts of dān she¯n
(Salviae Miltiorrhizae Radix) and hóng
huā (Carthami Flos).
i.v. Blank
control
None Not
described
Yes Contrast medium-induced renal
impairment was defined as Scr rise
>44.2 μM or >25% of basal level
within 3 days after exposure to
contrast medium, excluding other
etiology
Yu et al [86] 52 (27, 25) Random number
table
Qishen Huoxue Granule, a commercial
product comprising extracts of huáng qí
(Astragali Radix), dān she¯n (Salviae
Miltiorrhizae Radix), chì sháo (Paeoniae
Radix Rubra), chuān xio¯ng (Chuanxiong
Rhizoma), hóng huā (Carthami Flos),
dāng guı¯ (Angelicae Sinensis Radix).
By
gavage
Blank
control
None Not
described
Yes RIFLE criteria
Sheng et al [87] 60 (30, 30) Not described A decoction of 11 herbs, including
shān yào (Dioscoreae Rhizoma), she¯ng dì
(Rehmanniae Radix), shān zhu¯ yú (Corni
Fructus), zé xiè (Alismatis Rhizoma), fú
líng (Poria), mu˘ dān pí (Moutan Cortex),
huáng qí (Astragali Radix), che¯ qián căo
(Plantaginis Herba), bái máo ge¯n
(Imperatae Rhizoma), jı¯n qián căo
(Lysimachiae Herba), hăi jı¯n shā (Lygodii
Spora).
p.o. Blank
control
None Yes Yes Rise in urinary NAG, γ-GT and β2-
microglobulin
Fu et al [88] 150 (76, 74) Not described Chongcao Shenkang Capsules, a
commercial product mainly comprising
dān she¯n (Salviae Miltiorrhizae Radix),
huáng qí (Astragali Radix) and do¯ng
chóng xià căo (Cordyceps).
p.o. or
by
gavage
Blank
control
None Not
described
Yes 1985 national criteria for
diagnosing hemorrhagic fever with
renal syndrome.
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Capsules (2.7 g, p.o. or by gavage, thrice daily) till the end of
polyuric phase. Patients in the treatment group had
significantly shorter oliguric and polyuric periods than
those in the control group. Proteinuria and Scr in the
treatment group returned to normal ranges within signifi-
cantly shorter time than the control group. Furthermore,
serum and urinary β2-microglobulin levels of the treatment
group were significantly lower than those of the control
group on the fifth and tenth days after treatment. The
treatment group also had significantly lower incidence of
severe complications[88].
2. Reports indexed in Chinese database (Table 6)
Bailing Capsule for established AKI in ICU patients with acutely
exacerbating chronic obstructive pulmonary disease 40 patients
treated by routine therapy, including control of infection,
non-invasive ventilation, treatment of asthma and improving
homeostasis, were compared with 42 patients treated by
routine therapy plus oral or gavage administration of Bailing
Capsule, a proprietary fermented dōng chóng xià ca ̆o
(Cordyceps). After 12 days, the treatment group presented
significantly reduced BUN and Scr, with higher estimated
glomerular filtration rate (eGFR) and urinary output[89].
Jinshuibao Capsule for prevention of AKI in patients with
severe brain injury 53 patients treated by routine therapy
(preventing brain edema, hemorrhage, spasm of brain blood
vessels and protecting gastric mucosa) were compared with
54 patients treated by routine therapy plus oral or gavage
administration of Jinshuibao Capsule, a proprietary fermen-
ted dōng chóng xià căo (Cordyceps) powder for 5-10 days.
The Jinshuibao Capsule treatment group presented signifi-
cantly lower Scr and less AKI severity according to the RIFLE
criteria[90].
“Shennong 33”, a five-herb formula, used for the treatment of
AKI caused by a variety of etiologies 30 patients treated by
routine therapy, including removal of etiology, control of
infection, maintaining water and electrolyte homeostasis,
supply of nutrients, correction of acidosis, blood transfusion,
expectant and supporting treatment (including hemodialy-
sis), were compared with 34 patients treated by routine
therapy plus injections of “Shenong 33”. The treatment
group needed fewer hemodialysis, had significantly shorter
period of anuria and oliguria, and took significantly shorter
time for BUN, Scr and urinary protein excretion to recover to
normal ranges[91].
An alkalinized four-herb retention enema (“rectal dialysis”)
for pediatric AKI due to acute glomerulonephritis or
nephrosis In a study of pediatric AKI (2–12 years old), 16
patients treated by routine therapy, including control of
infection, diuretics, antihypertensives, steroid hormones,
water, electrolyte and acid-base homeostasis, were compared
with 22 patients treated by routine therapy plus rectal
treatment with a four-herb aqueous decoction plus 18 ml
5% sodium bicarbonate, up to 8 times per day until renal
function recovered. The treatment significantly accelerated
decline of BUN, recovery of urinary volume and clinical cure
of the primary glomerular diseases[92].
A three-ingredient retention enema for treatment of AKI
complication due to epidemic hemorrhagic fever 30 patients
treated by 20% mannitol (125 ml, p.o., twice daily) and
metoclopramide, (20 mg, i.m., twice daily) were compared
with 30 patients treated by rectal administration of a three-
ingredient decoction, twice daily. All patients were offered
routine therapy, including water intake restriction, diuretics
and expectant treatment. Both treatments were equally
effective in terms of declining BUN, recovering urinary
volume and urinary protein level and clinical cure of
epidemic hemorrhagic fever[93].
Gavage and retention enema of a five-ingredient decoction for
AKI in patients with cerebral hemorrhage 25 patients
treated by “Western medicine” routine therapy (including
water intake restriction and diuretics) were compared with 25
patients treated by routine therapy plus gavage (50 ml) and
rectal administration (100 ml) of a five-ingredient decoction,
thrice daily. The gavage and enema treatment significantly
reduced Scr and increased urine volume[94].
Gavage and retention enema of a five-ingredient decoction for
AKI in patients after cranial surgery 25 patients treated by
routine therapy (including reducing cranial pressure, anti-
inflammatory agents, and expectant treatments; use of
diuretics not stated) were compared with 25 patients treated
by routine therapy plus diuretics and gavage (50 ml) and
rectal administration (100 ml) of a five-ingredient decoction,
thrice daily. The diuretics, gavage and enema treatment
group significantly reduced Scr and increased urine
volume[95].
Retention enema of a seven-ingredient decoction for mannitol-
induced AKI in patients with cerebral hemorrhage, infarction
or subarachnoid hemorrhage Rectal administration of a
seven-ingredient decoction, once daily, was reported to be
more effective to recover Scr and BUN in 2–5 days than
20–100 mg/day furosemide i.m. or i.v. or a diuretic mixture
(regilin, dopamine & furosemide), i.v., 10 patients/group[96].
Retention enema of a five-herb decoction for pediatric AKI of
unspecified etiology: 22 patients treated by routine therapy,
including water and sodium intake restriction, low protein
diet, treatment of disorders of acid-base and metabolite
homeostasis, diuretics, vasodilatating agents, antihyperten-
sives and antibiotics were compared with 26 patients treated
by routine therapy plus rectal administration of a 5-herb
decoction. The enema treatment group was found to present
significantly lower BUN and Scr[97].
Jiushentang, a nine-herb formula, for oliguric AKI of a variety
of etiologies, excluding urinary obstruction and pre-renal
oliguria: 32 patients treated by routine therapy, including
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Table 6. Herbal medicine prevention and treatment of AKI: Analysis of the 14 randomized controlled trials indexed in Chinese databases but not in Pubmed.
Authors
Total subject
No. (control,
treatment)
Rando-
mization
method Herbal medicines Route Control
Blind design &
concealment
of allocation
Consent and
ethical
approval
Baseline
compar-
ability
AKI diagnosis criteria and
other notes
Pan
et al. [89]
82 (40, 42) Not
described
(ND)
Bailing Granule, mainly
comprisng fermented
do¯ng chóng xià căo
(Cordyceps).
p.o. or by gavage Blank control None ND Yes 2006 AKI National Criteria of
China, which were based on
the AKIN criteria: Scr rise of
>26.5 μM or >50% Scr rise
from baseline within 48 h, or
urinary output <0.5 ml/kg/h
for more than 6 h.
Tang
et al [102]
435 in title, 436
in abstract, 36 if
adding number
for each group
ND Bailing Granule, mainly
comprisng fermented
do¯ng chóng xià căo
(Cordyceps).
p.o. Blank control None ND Yes AKI criteria in a paper
published in a Chinese
medical journal in 2004.
***The research and subject
number are so confusing that
this report has to be excluded
from review.
Pan
et al. [90]
107 (53, 54) Tossing coin Jinshuibao Capsule,
mainly comprisng
fermented do¯ng chóng xià
căo (Cordyceps).
p.o. or by gavage Blank control None ND Yes RIFLE AKI criteria.
Sun
et al. [91]
64 (30, 34) ND “Shennong 33”,
comprising Hóng huā
(Carthami Flos), chuān
xio¯ng (Chuanxiong
Rhizoma), chì sháo
(Paeoniae Radix Rubra),
dān she¯n (Salviae
Miltiorrhizae Radix), dāng
guı¯ (Angelicae Sinensis
Radix).
i.v. Blank control None ND ND 1992 National AKI criteria,
not clearly described.
Yan [92] 38 (16, 22) ND An alkalinized four-herb
retention enema,
comparising Dà huáng
(Rhei Radix et Rhizoma),
huáng qí (Astragali Radix),
dān she¯n (Salviae
Miltiorrhizae Radix), hóng
huā (Carthami Flos) plus
18 ml 5% sodium
bicarbonate.
Rectal
administration
Blank control None ND ND Not clearly defined.
Qian [93] 60 (30, 30) ND A three-ingredient
retention enema
comprising Dà huáng
Rectal
administration
20% mannitol 125 ml,
p.o., twice daily;
None ND Yes 1986 Nanjing criteria for the
prevention and treatment of
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Table 6. (Continued)
Authors
Total subject
No. (control,
treatment)
Rando-
mization
method Herbal medicines Route Control
Blind design &
concealment
of allocation
Consent and
ethical
approval
Baseline
compar-
ability
AKI diagnosis criteria and
other notes
(Rhei Radix et Rhizoma),
máng xiāo (Natrii Sulfas),
mu˘ lì (Ostreae Concha).
metoclopramide,
20mg, i.m., twice daily
epidemic hemorrhagic fever;
not clearly defined.
Qian
et al. [94]
50 (25, 25) ND A five-ingredient
decoction, comprising Dà
huáng (Rhei Radix et
Rhizoma), duàn lóng gu˘
(Mastodi Ossis Fossilia
Calcinata), duàn mu˘ lì
(Ostreae Concha
Calcinata), pú go¯ng yı¯ng
(Taraxaci Herba), yì mu˘
căo (Leonuri Herba).
Gavage and
rectal
administration
Blank control None ND Yes Scr>176 μM, BUN>10.1 mM,
lasting 5-6 days.
Ma et al. [95] 50 (25, 25) ND A five-ingredient
decoction, comprising Dà
huáng (Rhei Radix et
Rhizoma), duàn lóng gu˘
(Mastodi Ossis Fossilia
Calcinata), duàn mu˘ lì
(Ostreae Concha
Calcinata), pú go¯ng yı¯ng
(Taraxaci Herba), yì mu˘
căo (Leonuri Herba).
Gavage and
rectal
administration
Blank control None ND Yes Anuria or oliguria 2-5 days
after cranial operation, Scr
>176 μ M.
Meng
et al. [96]
20 (10, 10) ND A seven-ingredient
decoction, comprising Dà
huáng (Rhei Radix et
Rhizoma), dān she¯n
(Salviae Miltiorrhizae
Radix), pú go¯ng yı¯ng
(Taraxaci Herba), mu˘ lì
(Ostreae Concha), zhì fù zı˘
(Aconiti Radix Lateralis
Praeparata), tu˘ fú ling
(Smilacis Glabrae
Rhizoma), huái mı˘
(Sophorae Flos
Immaturus).
Rectal
administration
Furosemide i.m. or i.v.
or regilin, dopamine &
furosemide, i.v.
None ND ND Oliguria, BUN 9.3-22.8 mM,
Scr 186-442 μM 3-7 days
after mannitol treatment.
48 (22, 26) ND Blank control None ND Yes
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Table 6. (Continued)
Authors
Total subject
No. (control,
treatment)
Rando-
mization
method Herbal medicines Route Control
Blind design &
concealment
of allocation
Consent and
ethical
approval
Baseline
compar-
ability
AKI diagnosis criteria and
other notes
Deng
et al. [97]
A five-ingredient
decoction, comprising Dà
huáng (Rhei Radix et
Rhizoma), huáng băi
(Phellodendri Cortex), bái
tóu we¯ng (Pulsatillae
Radix), huái huā
(Sophorae Flos), xì xı¯n
(Asari Herba).
Rectal
administration
National draft diagnosis
criteria of pediatric AKI
published in 1997.
Huang
et al. [98]
67 (32, 35) ND Jiushentang, a decoction
of nine herbs: dà huáng
(Rhei Radix et Rhizoma),
zhı˘ shí (Aurantii Fructus
Immaturus), hòu pò
(Magnoliae Officinalis
Cortex), qiāng huó
(Notopterygii Rhizoma et
Radix), huáng qí (Astragali
Radix), dāng guı¯
(Angelicae Sinensis Radix),
zhì fù zı˘ (Aconiti Radix
Lateralis Praeparata), dān
she¯n (Salviae Miltiorrhizae
Radix), chuān xio¯ng
(Chuanxiong Rhizoma).
p.o. Blank control None ND Yes Urinary output <400 ml/24h;
Scr rise >88.4 μM or BUN rise
>3.57 mM within 24 h;
excluding urinary obstruction
and pre-renal oliguria.
Xia et al. [99] 98 (48, 50) ND Jiushen decoction,
decoctions with a core
formula: she¯ng shí gāo
(Gypsum Crudum), zhı¯ mu˘
(Anemarrhenae Rhizoma),
xuán she¯n (Scrophulariae
Radix), she¯ng dì huáng
(Rehmanniae Radix
(Exsiccata seu Recens)), jı¯n
yín huā(Lonicerae Flos),
lián qiào (Forsythiae
Fructus), she¯ng zhı¯ zı˘
(Gardeniae Fructus
Crudus), huáng qín
(Scutellariae Radix), dān
p.o. Blank control None ND Yes Auria for 48-124 hours;
therapeutic effects are
classified based improved
urinary output and decline of
BUN and Scr as reported in a
textbook (Shaoji Yang.
Infectious diseases. Beijing:
People’s Health Publishing
House. 2005; pp78)
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Table 6. (Continued)
Authors
Total subject
No. (control,
treatment)
Rando-
mization
method Herbal medicines Route Control
Blind design &
concealment
of allocation
Consent and
ethical
approval
Baseline
compar-
ability
AKI diagnosis criteria and
other notes
she¯n (Salviae Miltiorrhizae
Radix), chuān xio¯ng
(Chuanxiong Rhizoma),
chì sháo (Paeoniae Radix
Rubra), which is modified
according to TCM pattern
differentiation by adding
or subtracting herbs.
Lin
et al. [100]
49 (25, 24) ND Sheshangliangxue
mixture: bàn biān lián
(Lobeliae Chinensis
Herba), bái máo ge¯n
(Imperatae Rhizoma), chì
sháo (Paeoniae Radix
Rubra), mò hàn lián
(Ecliptae Herba).
p.o. Blank control None ND Yes 2006 AKI National Criteria of
China, which were consistent
with the AKIN criteria.
Li et al. [101] 98 (49, 49) ND A fourteen-ingredient
decoction, comprising Dà
huáng (Rhei Radix et
Rhizoma), má huáng
(Ephedrae Herba), guăng
mù xiāng (Aucklandiae
Radix), xìng rén
(Armeniacae Semen), huò
xiāng (Agastaches Herba),
cāng zhú (Atractylodis
Rhizoma), dà fù pí (Arecae
Pericarpium), zhı˘ shí
(Aurantii Fructus
Immaturus), chì sháo
(Paeoniae Radix Rubra),
táo rén (Persicae Semen),
shuı˘ zhì (Hirudo), zé xiè
(Alismatis Rhizoma; zhu¯
líng (Polyporus), we¯i gān
suì (Kansui Radix Tostum).
p.o. or by gavage Blank control None ND Yes AKI criteria published in a
Chinese internal medicine
textbook published in 2004.
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etiology and inciting factor treatment, hemodialysis, treat-
ment of disorders of acid-base and metabolite homeostasis,
nutritional support, control of infections and treatment of
complications, were compared with 35 patients treated by
routine therapy plus oral administration of Jiushentang. The
author stated that Jiushentang was significantly more effec-
tive to reduce BUN and Scr and to induce clinical resolution
of AKI, but the frequency and duration of hemodialysis were
not discussed[98].
Jiushen Decoction, a formula mainly comprising 11 herbs,
varied according to TCM diagnosis, for the treatment of
anuric AKI in epidemic hemorrhagic fever 48 patients
treated by routine therapy, including stabilizing homeostasis,
improving microcirculation, improving renal blood flow,
diuretics and expectant treatments were compared with 50
patients treated by routine therapy plus Jiushen decoctions,
which had a core formula of 11 herbs and was modified
according to TCM pattern differentiation by adding or
subtracting herbs. The Jiushen Decoction group had sig-
nificantly improved urinary output and reduced Scr and
BUN; hematological parameters and liver function improved
more rapidly in the Jiushen Decoction group[99].
Sheshangliangxue Mixture, a four-herb formula, for venomous
snake bite-induced AKI 25 patients treated by routine
therapy, including wound cleaning, local anesthesia, injection
of anti-venom serum, furosemide, glucocorticoid hormones
and dialysis (indicated when there was anuria for 24h or
oliguria for 48h, Scr ≥ 354 μM or serum potassium > 6.5
mM), were compared with 24 patients treated by routine
therapy plus Sheshangliangxue Mixture, 30 ml, p.o., thrice
daily. The Sheshangliangxue Mixture group presented sig-
nificantly shorter oliguric duration, fewer requirements for
dialysis treatments and enhanced therapeutic effects[100].
A fourteen-ingredient formula, for AKI induced by a variety of
etiology 49 patients treated by routine therapy, including
expectant treatment, etiological treatment, hemodialysis, treat-
ment of disorders of acid-base and metabolite homeostasis and
nutritional support were compared with 49 patients treated by
routine therapy plus oral or gavage administration of a 14-herb
decotion. The author stated that the herbal medicine group was
significantly more effective to reduce BUN and Scr and to
induce clinical resolution of AKI, but the frequency of
hemodialysis and the duration of inducing clinical cure of
AKI were not shown[101].
CONCLUDING REMARKS AND OUTLOOK
As far as we know, this is the first comprehensive review on
the potential therapeutic value of herbal medicines, especially
Chinese herbal medicines, in the prevention and treatment of
AKI. The hypotheses that herbal medicines could have
potentials to (i) prevent or mitigate induction of AKI; (ii)
promote repair or regeneration; (iii) promote extrarenal
clearance of uremic toxins; and (iv) prevent AKI progression
to CKD have each gained certain levels of support from
experimental and/or clinical reports.
The potential value for herbal medicines in prevention of
AKI has gained the most experimental support and is
especially noteworthy, in view that many AKIs such as those
induced by I/R, nephrotoxicants, sepsis, endotoxins and
contrast agents should be largely preventable. Although
most clinical trials reviewed in this study presented low-level
evidence, the indicative value of the clinical and experimental
reports should not be disregarded; major plants emerging
from these studies certainly warrant further investigation. To
encourage future research on these herbs for the prevention
and treatment of AKI, we have listed in Table 7 the most
reported ones, whether as single-herb remedies or as part of
multi-herb formulae.
In particular, 30% clinical studies focused on the applica-
tion of TCM-based enemas for promoting extrarenal clear-
ance of uremic toxins, an approach with good affordability
and likely suited for those with poor access to renal
replacement therapies. Most of these enemas contained dà
huáng (Rhei Radix et Rhizoma; Rheum officinale Baillon;
contains anthracenic purgatives), but detailed formulation
varied. Thus better-characterized formulations and better
clinical trials of such enemas may support TCM use for AKI
in developing regions. However, dilemma exists. On one
hand, centers with poor access to dialysis facilities and thus
most likely benefitting from enema therapies often lack
training in randomized controlled clinical trials; on the other
hand, centers with established clinical trial expertise most
likely have access to dialysis facilities and less likely need
such enema therapy. Collaborations between different types
of centers and provision of rigorous training on good
practices in designing and conducting clinical trials seem
plausible solutions to yield quality data and to ensure that
related ethical issues are not overlooked.
Experimental evidence has emerged to support probable
therapeutic value for herbal medicines in promoting repair
Table 7. Fourteen herbs most commonly prescribed in herbal remedies
for AKI (more than 5 citations in the reports summarised in Tables 1-6).
Herb
Number of citations
in Tables 1-6
Dà huáng (Rhei Radix et Rhizoma) 16
Dān she¯n (Salviae Miltiorrhizae Radix) 16
Huáng qí (Astragali Radix) 14
Sháo yào or chì sháo (Paeoniae Radix or
Paeoniae Radix Rubra)
8
Zé xiè (Alismatis Rhizoma) 8
Do¯ng chóng xià căo (Cordyceps) 7
Hóng huā (Carthami Flos) 7
Yín yáng huò (Epimedii Herba) 7
Chuān xio¯ng (Chuanxiong Rhizoma 6
Dāng guı¯ (Angelicae Sinensis Radix) 6
Fú líng (Poria) 6
Gān căo (gān căo (Glycyrrhizae Radix) 5
Yì mu˘ căo (Leonuri Herba) 5
Zhu¯ líng (Polyporus) 5
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and regeneration through kidney resident and possibly
pluripotent cells. This line of research represents a new
frontier that deserves further investment.
Another new frontier is to prevent chronic lesions follow-
ing AKI. Given that some herbal species with anti-fibrotic
properties such as Salvia miltiorrhiza, Astragalus membrana-
ceus, Schizandra sinensis, Cordyceps sinensis, and Ganoderma
lucidum have shown in vitro, in vivo and/or clinical promises
in AKI, research on herbal entities in preventing chronic
fibrotic lesions seems rational.
However, the usefulness of herbal medicines ultimately
depends on high-level quality control and clinical evidence.
We specifically wish to point out two major areas for
thorough improvements — quality control of herbal medi-
cines and good practice in clinical trials — both necessary to
support scientific integrity and reproducibility. Readers are
encouraged to refer to guidelines on reporting herbal
medicines (www.gp-tcm.org/links/#good-practice-guidelines)
and clinical trials (www.consort-statement.org).
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